Acute Renal Failure (ARF)/ Acute Kidney Injury – Pipeline Review, 2019

Acute renal failure (ARF)/ acute kidney injury refers to the condition where the kidneys suddenly are no longer able to conduct the filtration of the waste products from the blood. When the kidneys lack this ability to filter the waste products, it leads to the accumulation of the body’s wastes and the body’s chemical balance may be disturbed. Acute renal failure (ARF)/ acute kidney injury occurs very swiftly over a period of few days and often occur in hospitalized individuals, who are critically ill and often in intensive care.

Some of the symptoms of the acute renal failure (ARF)/ acute kidney injury includes decreased urine output, shortness of breath, fluid retention, fatigue, confusion, weakness and nausea amongst other symptoms. Current treatment of acute renal failure (ARF)/ acute kidney injury includes a range of strategies which is based on both, the treating of the underlying cause of kidney injury and the treating of complications until the kidneys recover. Some of the treatment strategies include the balancing of the fluids in the body, medications for the control of potassium, undertaking of dialysis for the removal of toxins from the blood and the administration of medications for the restoration of calcium levels.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for acute renal failure (ARF)/ acute kidney injury. For instance; CXA-10, which is being studied by Complexa, Inc., is currently in phase-2 clinical trials for the study of oral CXA-10 in primary focal segmental glomerulosclerosis (FSGS).

At present around 50% of the pipeline candidates for acute renal failure (ARF)/ acute kidney injury are in the phase-3 and phase-4 stage. Majority of the studies are sponsored by academic and research institutions. 

Report Description 

The report on ‘Acute Renal Failure (ARF)/ Acute Kidney Injury – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Acute Renal Failure (ARF)/ Acute Kidney Injury. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acute Renal Failure (ARF)/ Acute Kidney Injury. 

The report on ‘Acute Renal Failure (ARF)/ Acute Kidney Injury – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope 

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Acute Renal Failure (ARF)/ Acute Kidney Injury
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Acute Renal Failure (ARF)/ Acute Kidney Injury
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business